Abstract
Arachidonic acid metabolism plays a key role in atherothrombotic events affecting the coronary or cerebrovascular territory, as reflected by experimental studies based on biochemical measurements of eicosanoid biosynthesis and the results of inhibitor trials in these settings. Two cyclooxygenase (COX)-isozymes exist, COX-1 and COX-2, that differ in terms of regulatory mechanisms of expression, tissue distribution, substrate specificity, and susceptibility to inhibition by drugs. Whereas the role of COX-1 expressed in platelets in acute coronary syndromes and ischemic stroke is definitely established through several large clinical studies with aspirin, the role of COX-2 activity in these settings is still unclear, because this enzyme was characterized only recently (1991) and its inhibitors (coxibs) only became available in 1998. In this review, we discuss the different expression profile of COX-2-related enzymes in the cells actively involved in atherothrombosis, the role of these enzymes as cause of plaque “instability”, and the clinical consequences of their inhibition. Recent studies suggest that variable expression of transmembrane and downstream receptors, as well as genetic mutations represent important determinants of the functional consequences of COX-2 expression and inhibition in different clinical settings.
Keywords: Plaque, atherothrombosis, COX-2
Current Vascular Pharmacology
Title: Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Volume: 8 Issue: 4
Author(s): Francesco Cipollone, Elena Toniato, Stefano Martinotti and Andrea Mezzetti
Affiliation:
Keywords: Plaque, atherothrombosis, COX-2
Abstract: Arachidonic acid metabolism plays a key role in atherothrombotic events affecting the coronary or cerebrovascular territory, as reflected by experimental studies based on biochemical measurements of eicosanoid biosynthesis and the results of inhibitor trials in these settings. Two cyclooxygenase (COX)-isozymes exist, COX-1 and COX-2, that differ in terms of regulatory mechanisms of expression, tissue distribution, substrate specificity, and susceptibility to inhibition by drugs. Whereas the role of COX-1 expressed in platelets in acute coronary syndromes and ischemic stroke is definitely established through several large clinical studies with aspirin, the role of COX-2 activity in these settings is still unclear, because this enzyme was characterized only recently (1991) and its inhibitors (coxibs) only became available in 1998. In this review, we discuss the different expression profile of COX-2-related enzymes in the cells actively involved in atherothrombosis, the role of these enzymes as cause of plaque “instability”, and the clinical consequences of their inhibition. Recent studies suggest that variable expression of transmembrane and downstream receptors, as well as genetic mutations represent important determinants of the functional consequences of COX-2 expression and inhibition in different clinical settings.
Export Options
About this article
Cite this article as:
Cipollone Francesco, Toniato Elena, Martinotti Stefano and Mezzetti Andrea, Genetic and Molecular Determinants of Atherosclerotic Plaque Instability, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330825
DOI https://dx.doi.org/10.2174/157016110791330825 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Virtual Screening Strategies in Medicinal Chemistry: The State of the Art and Current Challenges
Current Topics in Medicinal Chemistry Microcirculatory Endothelial Dysfunction During Endotoxemia - Insights into Pathophysiology, Pathologic Mechanisms and Clinical Relevance
Current Vascular Pharmacology Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Oxidative Stress, Inflammation and Endothelial Biomarkers in Arterial Hypertension
Current Hypertension Reviews Efficacy and Cardiovascular Safety of Antidiabetic Medications
Current Drug Safety Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Lifestyle Changes and Pharmacological Risk Factor Modification for Effective Vascular Disease Prevention
Vascular Disease Prevention (Discontinued) Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Clinical Pharmacotherapy and Drug Development for Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Preface [Hot Topic: Recent Progress in Cardiovascular Gene Therapy;Emerging to Real Drug? (Guest Editor: Ryuichi Morishita)]
Current Gene Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical Design Application of Stem Cells in Cardiology: Where we are and where we are Going
Current Stem Cell Research & Therapy Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Association of Selected Adipocytokines and Inflammatory Markers on Body Mass Index in Type 2 Diabetes Patients in Saudi Arabia and as Risk Factors to Cardiovascular Disease
Current Diabetes Reviews